anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a traditional Chinese preparation for treating rhinitis and a preparation method thereof. The traditional Chinese preparation for treating rhinitis is prepared from the following raw materials and auxiliary materials in parts by weight: 1-8 parts of magnolia biondii pamp volatile oil or magnolia biondii pamp volatile oil mixture, 1-6 parts of borneolum syntheticum, 1-3 parts of peppermint oil, 10-40 parts of absolute ethyl alcohol, 20-80 parts of tween-80 and 5-40 parts of purified water, thus being made into spraying agent. The invention has the advantages that: compared with the prior art, the formula constitution is clear, the preparation has obvious curative effects on treating acute and chronic and allergic rhinitis. In addition, the preparation method is simple and convenient for process, and thus the quality is easy to control. The preparation does not contain ephedrine or nemazoline, thus overcoming the side effect of causing medicamentous rhinitis and the like easily caused by long-time administration of other medicaments. People are administrated by directly spraying the nasal cavity, the advantages of uniform local administration, fast adsorption and action, and obvious curative effect can be achieved. The traditional Chinese preparation is effective on the rhinitis and has no toxic and side effects.
Patients receive daratumumab IV over 45 minutes. Two hours later, patients receive 111In-DOTA-daratumumab and 225Ac-DOTA-daratumumab IV over 20-30 minutes.
Necrophagous flies, particularly blowflies, serve as vital indicators in forensic entomology and ecological studies, contributing to minimum postmortem interval estimations and environmental monitoring. The study investigates variations in the predominant cuticular hydrocarbons (CHCs) viz. n-C25, n-C27, n-C28, and n-C29 of empty puparia of Calliphora vicina Robineau-Desvoidy, 1830, (Diptera: Calliphoridae) across diverse environmental conditions, including burial, above-ground and indoor settings, over 90 days. Notable trends include a significant decrease in n-C25 concentrations in buried and above-ground conditions over time, while n-C27 concentrations decline in buried and above-ground conditions but remain stable indoors. Burial conditions show significant declines in n-C27 and n-C29 concentrations over time, indicating environmental influences. Conversely, above-ground conditions exhibit uniform declines in all hydrocarbons. Indoor conditions remain relatively stable, with weak correlations between weathering time and CHC concentrations. Additionally, machine learning techniques, specifically Extreme Gradient Boosting (XGBoost), are employed for age estimation of empty puparia, yielding accurate predictions across different outdoor and indoor conditions. These findings highlight the subtle responses of CHC profiles to environmental stimuli, underscoring the importance of considering environmental factors in forensic entomology and ecological research. The study advances the understanding of insect remnant degradation processes and their forensic implications. Furthermore, integrating machine learning with entomological expertise offers standardized methodologies for age determination, enhancing the reliability of entomological evidence in legal contexts and paving the way for future research and development.
Abstract The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self buffering protein fonnulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, especially, in particular, for the treatment of diseases in human subjects.
Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. participants will walk or jog pre-determined routes in trails of an urban forest (Pacific Spirit Park).
T cells, compositions, and methods for treating cancer. The methods include a method of generating T cells capable of infiltrating a tumour of a human and participating in an immune response against the tumour; and a method of treating cancer comprising administering to a human afflicted with a tumour a therapeutically effective amount of T cells that mediate tumour regression, the T cells having been either isolated from the tumour of the human after immunization of the human with a composition comprising hapten-modified tumor cells and/or expanded in vitro from T cells thus isolated. Malignant tumour cells selected from the group melanoma, lymphoma, adenocarcinoma, sarcoma and non-solid tumours. The use is selected from the group consisting of melanoma, ovarian, colon, breast, rectal, lung, kidney, prostate cancer and leukemia. The adjuvant used is selected from the group consisting of Bacille Calmette-Guerin, Q-21 and detoxified endotoxin. The hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(sulfonic 1-naphtyl) ethylene diamine, trinitrobenzenesulfonic acid and dinitrobenzene-S-mustard.
PURPOSE OF REVIEW: Hereditary cancer risk assessment and counseling have become integral in oncology care, especially in breast and gynecologic malignancies where genetic test results impact management. However, a large number of patients who could benefit from genetic testing are not getting tested. As such, genetic risk assessment and counseling methods have had to evolve to meet the needs of this expanding patient population.
RECENT FINDINGS: "Mainstreaming" genetic testing is an initiative to incorporate genetic testing into routine cancer care in lieu of the traditional genetic counseling model to improve uptake of testing while minimizing expansion of genetic counselor and clinic resources. These models have performed well in various institutions demonstrating an improvement in clinical efficacy. However, missed opportunities from the preventive care standpoint, a core value of cancer genetics risk assessment, have become apparent. The focus of these models is on the patient's cancer diagnosis and comprehensive/familial genetic risk assessment is not often completed.
SUMMARY: Identifying patients at an increased risk of cancer, even in the absence of a hereditary cancer predisposition syndrome, is important in tailoring screening and preventive measures. As we look to the future, we need to critically approach mainstreaming and determine how to reincorporate comprehensive genetic risk assessment into our models.
The invention discloses a slow release/controlled release tablet for inhibiting breast cancer tumor activity and a preparation method thereof. The slow release/controlled release tablet comprises metformin hydrochloride and gdc0941 as active components and pharmaceutically acceptable accessory materials. The preparation method has simple processes, can be operated easily and can enlarge production. An external antineoplastic test proves that metformin hydrochloride and gdc0941 can produce anticancer activity synergism. Through combination of metformin hydrochloride and gdc0941, high anticancer activity is obtained. The slow release/controlled release tablet containing metformin hydrochloride and gdc0941 has stable components, produces effects for a long time and is worthy of clinical popularization.
The invention relates to a mutant Cβ protein comprising the amino acid sequence A-X1X2X3X4X5X6X7X8X9X10X11X12-B, wherein A comprises amino acids 1-164 of the sequence shown in Fig. 1 (SEQ ID NO: 2), B represents a sequence starting from amino acid 177 and terminating at an amino acid between residue 1094 and 1127, inclusive, of the sequence shown in Fig. 1 (SEQ ID NO: 2), and X1 - X12 are each selected independently from the group consisting of Ala, Val, Leu, Ile, Pro, Met, Phe, Trp, a bond, and the wild type amino acid found at the corresponding position of the sequence shown in Fig. 1 (SEQ ID NO: 2), wherein said amino acid positions are numbered from the first amino acid of the native amino acid sequence encoding said protein, with the proviso that at least one of X1 through X12, inclusive, is other than the wild type amino acid, and wherein the LPXTG motif may be missing from the mutant Cβ protein. The invention also relates to a polynucleotide molecule encoding a mutant Cβ protein, as well as vectors comprising such polynucleotide molecules, and host cells transformed therewith. The invention also relates to a conjugate comprising the mutant Cβ protein covalently conjugated to a capsular polysaccharide. The invention also relates to a vaccine comprising at least one mutant Cβ protein of the invention and a pharmaceutically acceptable carrier. The invention also relates to a method of inducing an immune response in an animal, comprising administering the vaccine of the invention to an animal in a therapeutically effective amount.
The 4-valent (4 v) and 9-valent (9 v) human papillomavirus (HPV) vaccines are approved in China for females aged 9-45 years. However, the real-world impact of 4vHPV or 9vHPV vaccination for the prevention of high-grade cervical disease in Chinese women is lacking. Two post-marketing surveillance studies will be conducted to measure the occurrence of high-grade cervical lesions in Chinese women who had received ≥1 dose of the 4vHPV (aged 20-45 years) or 9vHPV (aged 16-26 years) vaccine in Ningbo, China. Vaccination data will be extracted from the Ningbo Regional Health Information Platform (NRHIP) from the date of the first 4vHPV (January 9, 2018) or the first 9vHPV (January 25, 2019) vaccination to March 31, 2021. The primary 4vHPV and 9vHPV vaccinated cohorts will include women vaccinated per protocol. The 4vHPV/9vHPV vaccinated test-negative (cervical HPV negative; ThinPrep cytology test negative) and corresponding matched unvaccinated HPV test-negative sub-cohorts will also be assessed. Outcomes will be the occurrence of new-onset cervical intraepithelial neoplasia grade 2/3, adenocarcinoma in situ, and invasive cervical cancer. This study aims to demonstrate that such a methodological approach is feasible and can be used to assess the impact of HPV vaccination in other regions across China.
SSI (soft tissue infection) is an aggravating risk specifically associated with implants. Breast reconstruction quotes infection rates anywhere from 1-35% while cosmetic augmentations quote rates around 1.5%. Usually, the causative organisms are skin flora like Staph aureus and Staph epidermidis. Occasionally mycobacterium and other atypical bacterium are isolated more commonly in the immunocompromised. Despite perioperative antibiotics, SSI is still a prevalent complication increasing total expenditure of patients and hospital systems upwards of $4000/patient in reoperation fees and hospital stay costs. Skin prep and antibiotics in the preoperative phase is very important to the sterile technique and decreasing risk of infection by decreasing bacterial load at the time of incision and surgery. However, postoperative care and interventions are less strictly evaluated and defined. Currently, there is no standard of care in regards to showering post operatively with JP (Jackson-Pratt) drains in place. Timing of showering is ultimately based on surgeon preference. In practice, the investigators routinely have had patients wait to shower until the JP drains are removed. The investigators hypothesize that showering daily, even with drains in place, will not increase rates of infection in breast reconstruction and perhaps improve quality of life during first stage. This study is prospective with participants randomized to either shower daily after 48hrs or standard of care and shower after drains removed. The participants will be asked to fill out a quality of life survey 90 days after enrollment. The patients will also be monitored for signs of infection for 90 days.
PURPOSE:To easily insert the title tampon in a short time and effectively stop blood by the absorption of blood by compression-molding the pulp fiber for absorbing product to the dimension suitable for the insertion into the nosal cavity and applying the external antibacterial. CONSTITUTION:The material of an absorbing product is the purified cellulose pulp, and possesses the superior liquid absorbing faculty. The title article is compression- molded into a cylinder form having the dimension suitable for the insertion into nasal cavity. In order to facilitate taking-off, an operation thread made of Teflon is preferably embedded. An external antibacterial has a healing ointment and uniformly applied onto a gauze pad, and the antibiotic e.g. Dibekacin sulfate(R) is preferably used in consideration of the antibacterial spectrum and effective growth suppressing concentration. Vaseline, carbowax, lanolin, etc., are used as the ointment base, and added into the external antibacterial, and the antiphlogistic analgestic can be contained, and lightens the dolor in the removal of the thread. Sterilization is executed, for example, in the circulation steam sterilization at 100 deg.C for 30min., and the tampon is sealed into a sterilizing bag to prevent the imbibition to steam. When blood oozes out from a nose mucosa, the hemostatic tampon absorbs blood and imbibes and presses a bleeding part and effectively stops bleeding.
Children with complex special health care needs are those children who have multiple, complex, chronic health conditions who require health and related services of a type or amount beyond that required by children generally. When these children are hospitalized, they receive services as part of an integrated system that provides centralized record keeping and care orders, clearly identified roles and methods of communication for health professionals involved in their care, an established method to obtain equipment and supplies, and regular monitoring of the child's condition. However, when the same child is cared for at home, services are often fragmented, and rarely accessed and delivered in a coordinated system. The task of coordinating services and sharing information between providers almost always becomes the responsibility of the parent or guardian. Families report that their greatest challenges are the stress of coordinating multiple providers, and the disconnect and lack of communication between services and providers. This study will address these issues, using an advanced practice nurse (APN) program of telehealth care coordination and case management in support of these families. Either the telephone or telephone plus interactive video are used by an advanced practice nurse to provide care coordination and case management. Goals of the program are to (1) reduce the number of crisis or unplanned uses of health care services and increase the number of non-crisis or planned health care service usage, (2) improve the QL (quality of life) for these children and their families, and (3) reduce the deficit between help needed and help received for the families in caring for these children. The study objective will be accomplished using a three armed randomized controlled trial. Children will be randomized into a control group receiving usual care that includes LPN (Licensed practical nurse)-delivered care coordination and RN (registered nurse)-delivered telephone triage, an intervention group receiving APN-delivered telephone care coordination and case management, and another intervention group receiving APN-delivered telephone + video care coordination and case management services. It is hypothesized that as the level of telehealth use in coordination and management increases the utilization of unplanned, or crisis, health care service utilization will decrease, that families will receive more of their needed care, and quality of life for the children and their families will improve
The arm #1 consists of 6 eligible patients who receive Acetazolamide 250mg once daily an hour before sleep for first six nights and after two weeks washout they receive placebo for six nights in the same order. After each six-day period they undergo polysomnography.
Buprenorphine and Naloxone Sublingual Tablets, USP are available in two dosage strengths intended for sublingual administration as follows: 2 mg buprenorphine with 0.5 mg naloxone free bases and 8 mg buprenorphine with 2 mg naloxone free bases. Each tablet also contains citric acid anhydrous, corn starch, FD & C yellow no. 6, lactose monohydrate, lemon-lime flavor, magnesium stearate, mannitol, povidone, sodium citrate dihydrate and sucralose. 

Chemically, buprenorphine HCl is (6R, 7R, 14S)-17-Cyclopropylmethyl-7,8-dihydro-7-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-O--methyl-6,14-ethano-17-normorphine hydrochloride. It has the following chemical structure:

Buprenorphine hydrochloride, USP has the molecular formula C29H41NO4 • HCl and the molecular weight is 504.1. It is a white to almost white crystalline powder, sparingly soluble in water, freely soluble in methanol, soluble in alcohol, and practically insoluble in cyclohexane.

Chemically, naloxone HCl dihydrate, USP is 17-Allyl-4, 5 α-epoxy-3, 14-dihydroxymorphinan-6-one hydrochloride dihydrate. It has the following chemical structure:

Naloxone hydrochloride dihydrate has the molecular formula C19H22ClNO4,2H2O and the molecular weight is 399.9. It is a white to slightly off-white powder or almost white crystalline powder and is freely soluble in water, soluble in alcohol, and practically insoluble in toluene and ether.
FIELD: medicine, physiology, pathophysiology, pharmacology. SUBSTANCE: the end product is isolated from peony roots bark (Paeonia lutea). Roots are peeled, washed with cold water and dried at 36.5-37.5 C for 23-25 h. Dried bark is separated, milled to granular-powder-like state, poured with 40% ethyl alcohol (10 ml of alcohol per 1 g of powder) and infused for 5-7 days in dark. Precipitate is removed and supernatant is brought about to the initial volume with distilled water. After oral administration of the preparation to animals the total fibrinolytic activity is increased by 1.6-fold, activity of plasminogen activator - by 2-fold, activated partial thromboplastin time is increased by 1.4-fold and blood glucose content in development of experimental insulin-dependent diabetes mellitus is decreased. Invention can be used for preparing biologically active preparation showing an anticoagulant effect. EFFECT: broadened assortment of preparations and their spectrum of effects. 3 cl, 1 tbl, 3 ex
BACKGROUND: The primary purpose of this review is to synthesise the effect of strategies aiming to sustain the implementation of evidenced-based interventions (EBIs) targeting key health behaviours associated with chronic disease (i.e. physical inactivity, poor diet, harmful alcohol use, and tobacco smoking) in clinical and community settings. The field of implementation science is bereft of an evidence base of effective sustainment strategies, and as such, this review will provide important evidence to advance the field of sustainability research.
METHODS: This systematic review protocol is reported in accordance with the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) checklist. Methods will follow Cochrane gold-standard review methodology. The search will be undertaken across multiple databases, adapting filters previously developed by the research team, data screening and extraction will be performed in duplicate, strategies will be coded using an adapted sustainability-explicit taxonomy, and evidence will be synthesised using appropriate methods (i.e. meta-analytic following Cochrane or non-meta-analytic following SWiM guidelines). We will include any randomised controlled study that targets any staff or volunteers delivering interventions in clinical or community settings. Studies which report on any objective or subjective measure of the sustainment of a health prevention policy, practice, or programme within any of the eligible settings will be included. Article screening, data extraction, risk of bias, and quality assessment will be performed independently by two review authors. Risk of bias will be assessed using Version 2 of the Cochrane risk-of-bias tool for randomised trials (RoB 2). A random-effect meta-analysis will be conducted to estimate the pooled effect of sustainment strategies separately by setting (i.e. clinical and community). Sub-group analyses will be undertaken to explore possible causes of statistical heterogeneity and may include the following: time period, single or multi-strategy, type of setting, and type of intervention. Differences between sub-groups will be statistically compared.
DISCUSSION/CONCLUSION: This will be the first systematic review to determine the effect of strategies designed to support sustainment on sustaining the implementation of EBIs in clinical and community settings. The findings of this review will directly inform the design of future sustainability-focused implementation trials. Further, these findings will inform the development of a sustainability practice guide for public health practitioners.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022352333.